Allspring Global Investments Holdings LLC Has $330.23 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,808,002 shares of the medical research company’s stock after acquiring an additional 47,221 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Charles River Laboratories International were worth $330,231,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the period. Mizuho Securities USA LLC increased its position in shares of Charles River Laboratories International by 2,336.4% during the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock worth $19,081,000 after acquiring an additional 92,895 shares in the last quarter. Premier Fund Managers Ltd raised its holdings in shares of Charles River Laboratories International by 56.3% during the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock worth $49,573,000 after acquiring an additional 90,000 shares during the period. JPMorgan Chase & Co. lifted its position in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new position in Charles River Laboratories International during the 3rd quarter worth about $83,800,000. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on CRL. Bank of America cut their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. UBS Group reiterated a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research note on Monday, November 18th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $154.93 on Wednesday. Charles River Laboratories International, Inc. has a 12-month low of $154.01 and a 12-month high of $275.00. The company’s 50 day moving average price is $178.90 and its two-hundred day moving average price is $192.24. The firm has a market cap of $7.92 billion, a PE ratio of 19.39, a PEG ratio of 6.47 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).